Study on Long-Term Health of Adults from a Previous Melanoma Treatment Study
Sponsor: Regeneron Pharmaceuticals
ClinicalTrials ID:NCT06848088
This study is examining the long-term health effects of two experimental drugs, fianlimab and cemiplimab, in adults with advanced melanoma who participated in a previous study. The focus is on monitoring cancer status and overall health without administering any study drugs.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to understand the long-term safety and effectiveness of two experimental drugs, fianlimab and cemiplimab, in people with advanced melanoma who were part of an earlier study. Participants will not receive any study drugs during this follow-up. Instead, their cancer status and general health will be monitored as part of their routine care. The study will also gather information about any other treatments participants may have received since the previous study.
Eligibility Criteria
Inclusion Criteria
- Participants must have melanoma and have been part of specific groups (cohorts 6, 15, or 16) in the previous study R3767-ONC-1613 (NCT03005782).
Exclusion Criteria
None
Note: Other protocol-defined Inclusion/ Exclusion criteria may apply
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| The Angeles Clinic and Research Institute - West Los Angeles Office | 90025 | Los Angeles | California |
| California Pacific Medical Center | 94115 | San Francisco | California |
| University of Colorado Anschutz Medical Campus | 80045 | Aurora | Colorado |
| Henry Ford Hospital | 48202 | Detroit | Michigan |
| Cancer & Hematology Centers of Western Michigan | 49546 | Grand Rapids | Michigan |
| Sarah Cannon Research Institute | 37203 | Nashville | Tennessee |
| South Texas Oncology And Hematology | 78229 | San Antonio | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.